Shanghai Celliver Biotechnology

Shanghai Celliver Biotechnology is a clinical-stage biotechnology company focused on the development of induced pluripotent stem cell (iPSC) derived cell therapies and organoid-based drug discovery platforms. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company leverages its proprietary 'Cell-to-Liver' technology to create functional hepatocytes for the treatment of end-stage liver diseases and metabolic disorders. Their pipeline primarily targets indications such as acute-on-chronic liver failure (ACLF) and cirrhosis, aiming to provide scalable alternatives to traditional organ transplantation. In addition to therapeutic development, Celliver provides high-throughput organoid screening services to pharmaceutical partners for toxicity testing and disease modeling. The company is backed by prominent venture capital firms and maintains a strong focus on regenerative medicine and bioengineering.